Primary obesity surgery endoluminal (POSE-2) procedure for treatment of obesity in clinical practice.
Journal
Endoscopy
ISSN: 1438-8812
Titre abrégé: Endoscopy
Pays: Germany
ID NLM: 0215166
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
aheadofprint:
27
11
2020
pubmed:
28
11
2020
medline:
6
11
2021
entrez:
27
11
2020
Statut:
ppublish
Résumé
The POSE-2 procedure shortens and narrows the stomach using multiple full-thickness plications in the gastric body. We studied the efficacy and safety of POSE-2 for obesity at 1 year in a real-world setting. We reviewed the records of 75 patients who underwent POSE-2 at our unit. The primary outcome was percentage total body weight loss (%TBWL) at 1 year. Secondary outcomes were safety and durability. We used linear mixed model analysis. 46 patients completed 1 year. Mean age and body mass index (BMI) were 49.3 years (standard deviation [SD] 10.2) and 38.2 kg/m POSE-2 induced significant weight loss at 1 year. It appears to be safe, durable, and required only a short hospital stay.
Sections du résumé
BACKGROUND
The POSE-2 procedure shortens and narrows the stomach using multiple full-thickness plications in the gastric body. We studied the efficacy and safety of POSE-2 for obesity at 1 year in a real-world setting.
METHODS
We reviewed the records of 75 patients who underwent POSE-2 at our unit. The primary outcome was percentage total body weight loss (%TBWL) at 1 year. Secondary outcomes were safety and durability. We used linear mixed model analysis.
RESULTS
46 patients completed 1 year. Mean age and body mass index (BMI) were 49.3 years (standard deviation [SD] 10.2) and 38.2 kg/m
CONCLUSION
POSE-2 induced significant weight loss at 1 year. It appears to be safe, durable, and required only a short hospital stay.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1169-1173Commentaires et corrections
Type : CommentIn
Informations de copyright
Thieme. All rights reserved.
Déclaration de conflit d'intérêts
Gontrand Lopez Nava is a paid consultant for Apollo Endosurgery, USGI Medical, USA and Nitinotes. All other authors declare that they have no conflicts of interest.